{"transactions":[{"id":697160,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-04T21:22:36.000Z","date":"2026-07-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":194791,"price":3.38,"value":658393.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld to pay tax withholding obligations due on the date of settlement."}],"balance_after":168663,"source":{"system":"sec-edgar","filing":"0001193125-26-333136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000119312526333136/ownership.xml","form_type":"4"}},{"id":697159,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-04T21:22:36.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":354454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023."}],"balance_after":363454,"source":{"system":"sec-edgar","filing":"0001193125-26-333136","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000119312526333136/ownership.xml","form_type":"4"}},{"id":697328,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-08-04T21:22:10.000Z","date":"2026-07-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":72138,"price":3.38,"value":243826.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld to pay tax withholding obligations due on the date of settlement."}],"balance_after":81215,"source":{"system":"sec-edgar","filing":"0001193125-26-333133","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000119312526333133/ownership.xml","form_type":"4"}},{"id":697327,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-08-04T21:22:10.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":152353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023."}],"balance_after":153353,"source":{"system":"sec-edgar","filing":"0001193125-26-333133","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000119312526333133/ownership.xml","form_type":"4"}},{"id":937078,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69238,"kind":"person","name":"Kirk Allan","position":1,"cik":"0001995409","reported_name":"Kirk Allan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-16T22:00:07.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":false,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001193125-26-015487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015487/ownership.xml","form_type":"4"}},{"id":937077,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69238,"kind":"person","name":"Kirk Allan","position":1,"cik":"0001995409","reported_name":"Kirk Allan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T22:00:07.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":3430,"source":{"system":"sec-edgar","filing":"0001193125-26-015487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015487/ownership.xml","form_type":"4"}},{"id":937080,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-16T22:00:06.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":false,"shares":8575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8575},"source":{"system":"sec-edgar","filing":"0001193125-26-015486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015486/ownership.xml","form_type":"4"}},{"id":937079,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T22:00:06.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":true,"shares":8575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":8575,"source":{"system":"sec-edgar","filing":"0001193125-26-015486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015486/ownership.xml","form_type":"4"}},{"id":937076,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":43099,"kind":"person","name":"Lee June","position":1,"cik":"0001696493","reported_name":"Lee June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-16T22:00:04.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":false,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001193125-26-015485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015485/ownership.xml","form_type":"4"}},{"id":937075,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":43099,"kind":"person","name":"Lee June","position":1,"cik":"0001696493","reported_name":"Lee June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T22:00:04.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":3430,"source":{"system":"sec-edgar","filing":"0001193125-26-015485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015485/ownership.xml","form_type":"4"}},{"id":937074,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-16T22:00:03.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":false,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001193125-26-015484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015484/ownership.xml","form_type":"4"}},{"id":937073,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T22:00:03.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":3430,"source":{"system":"sec-edgar","filing":"0001193125-26-015484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526015484/ownership.xml","form_type":"4"}},{"id":937150,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69246,"kind":"person","name":"McBride John S.","position":1,"cik":"0001618251","reported_name":"McBride John S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-16T17:00:10.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":false,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001193125-26-015489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1618251/000119312526015489/ownership.xml","form_type":"4"}},{"id":937149,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69246,"kind":"person","name":"McBride John S.","position":1,"cik":"0001618251","reported_name":"McBride John S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T17:00:10.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":3430,"source":{"system":"sec-edgar","filing":"0001193125-26-015489","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618251/000119312526015489/ownership.xml","form_type":"4"}},{"id":937357,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69252,"kind":"person","name":"Hillson Jan","position":1,"cik":"0001871936","reported_name":"Hillson Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-16T17:00:09.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":false,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001193125-26-015488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1871936/000119312526015488/ownership.xml","form_type":"4"}},{"id":937356,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69252,"kind":"person","name":"Hillson Jan","position":1,"cik":"0001871936","reported_name":"Hillson Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-16T17:00:09.000Z","date":"2026-01-10","kind":"exercise","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026."}],"balance_after":3430,"source":{"system":"sec-edgar","filing":"0001193125-26-015488","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871936/000119312526015488/ownership.xml","form_type":"4"}},{"id":1304306,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:09.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":66500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":66500,"derivative":{"underlying":"Common Stock","underlying_shares":66500},"source":{"system":"sec-edgar","filing":"0000950170-25-004923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000095017025004923/ownership.xml","form_type":"4"}},{"id":1304305,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:09.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 600,000 shares of common stock, which option vests with respect to 150,000 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":600000,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000950170-25-004923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000095017025004923/ownership.xml","form_type":"4"}},{"id":1304242,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84183,"kind":"person","name":"Little Paul Sean","position":1,"cik":"0001749385","reported_name":"Little Paul Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:08.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10, 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10, 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-004918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004918/ownership.xml","form_type":"4"}},{"id":1304241,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84183,"kind":"person","name":"Little Paul Sean","position":1,"cik":"0001749385","reported_name":"Little Paul Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:08.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 175,000 shares of common stock, which option vests with respect to 43,750 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":175000,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-004918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004918/ownership.xml","form_type":"4"}},{"id":1304240,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:07.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":8575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the restricted stock units will vest on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the restricted stock units will vest on January 10, 2026."}],"balance_after":8575,"derivative":{"underlying":"Common Stock","underlying_shares":8575},"source":{"system":"sec-edgar","filing":"0000950170-25-004922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004922/ownership.xml","form_type":"4"}},{"id":1304239,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:07.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":77175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 77,175 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026."}],"balance_after":77175,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":77175},"source":{"system":"sec-edgar","filing":"0000950170-25-004922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004922/ownership.xml","form_type":"4"}},{"id":1304370,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:06.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":27000,"derivative":{"underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000950170-25-004916","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000095017025004916/ownership.xml","form_type":"4"}},{"id":1304369,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:06.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":243000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 243,000 shares of common stock, which option vests with respect to 60,750 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":243000,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":243000},"source":{"system":"sec-edgar","filing":"0000950170-25-004916","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000095017025004916/ownership.xml","form_type":"4"}},{"id":1304236,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":43099,"kind":"person","name":"Lee June","position":1,"cik":"0001696493","reported_name":"Lee June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:05.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."}],"balance_after":3430,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0000950170-25-004915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004915/ownership.xml","form_type":"4"}},{"id":1304235,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":43099,"kind":"person","name":"Lee June","position":1,"cik":"0001696493","reported_name":"Lee June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:05.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":30870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026."}],"balance_after":30870,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":30870},"source":{"system":"sec-edgar","filing":"0000950170-25-004915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004915/ownership.xml","form_type":"4"}},{"id":1304238,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:04.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."}],"balance_after":3430,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0000950170-25-004920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004920/ownership.xml","form_type":"4"}},{"id":1304237,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:04.000Z","date":"2035-01-10","kind":"grant","planned":false,"acquired":true,"shares":30870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026."}],"balance_after":30870,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":30870},"source":{"system":"sec-edgar","filing":"0000950170-25-004920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004920/ownership.xml","form_type":"4"}},{"id":1304234,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69238,"kind":"person","name":"Kirk Allan","position":1,"cik":"0001995409","reported_name":"Kirk Allan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-13T22:30:03.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."}],"balance_after":3430,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0000950170-25-004914","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004914/ownership.xml","form_type":"4"}},{"id":1304233,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69238,"kind":"person","name":"Kirk Allan","position":1,"cik":"0001995409","reported_name":"Kirk Allan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:30:03.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":30870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026."}],"balance_after":30870,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":30870},"source":{"system":"sec-edgar","filing":"0000950170-25-004914","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025004914/ownership.xml","form_type":"4"}},{"id":1304391,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69252,"kind":"person","name":"Hillson Jan","position":1,"cik":"0001871936","reported_name":"Hillson Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-13T17:30:12.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."}],"balance_after":3430,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0000950170-25-004925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1871936/000095017025004925/ownership.xml","form_type":"4"}},{"id":1304390,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69252,"kind":"person","name":"Hillson Jan","position":1,"cik":"0001871936","reported_name":"Hillson Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T17:30:12.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":30870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026."}],"balance_after":30870,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":30870},"source":{"system":"sec-edgar","filing":"0000950170-25-004925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871936/000095017025004925/ownership.xml","form_type":"4"}},{"id":1304303,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69246,"kind":"person","name":"McBride John S.","position":1,"cik":"0001618251","reported_name":"McBride John S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-13T17:30:10.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":3430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the total restricted stock units will vest on January 10, 2026."}],"balance_after":3430,"derivative":{"underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0000950170-25-004924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1618251/000095017025004924/ownership.xml","form_type":"4"}},{"id":1304302,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69246,"kind":"person","name":"McBride John S.","position":1,"cik":"0001618251","reported_name":"McBride John S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T17:30:10.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":30870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026."}],"balance_after":30870,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":30870},"source":{"system":"sec-edgar","filing":"0000950170-25-004924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618251/000095017025004924/ownership.xml","form_type":"4"}},{"id":1304347,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Restricted Stock Units","published_at":"2025-01-13T17:30:06.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":64500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\"). The RSUs will vest with respect to 50% of the RSUs on January 10, 2027, and then with respect to the remaining 50% of the underlying shares on January 10 2028, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":64500,"derivative":{"underlying":"Common Stock","underlying_shares":64500},"source":{"system":"sec-edgar","filing":"0000950170-25-004921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000095017025004921/ownership.xml","form_type":"4"}},{"id":1304346,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T17:30:06.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":150500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,000 shares of common stock, which option vests with respect to 37,625 shares on January 10, 2026, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending January 10, 2029, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":150500,"derivative":{"exercise_price":4.04,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":150500},"source":{"system":"sec-edgar","filing":"0000950170-25-004921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000095017025004921/ownership.xml","form_type":"4"}},{"id":1354089,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84183,"kind":"person","name":"Little Paul Sean","position":1,"cik":"0001749385","reported_name":"Little Paul Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-22T22:00:09.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":525032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 525,032 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 196,887 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 328,145 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":525032,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":525032},"source":{"system":"sec-edgar","filing":"0000950170-24-130275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024130275/ownership.xml","form_type":"4"}},{"id":1354494,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-22T22:00:06.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":840438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 840,438 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 315,164 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 525,274 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":840438,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":840438},"source":{"system":"sec-edgar","filing":"0000950170-24-130273","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000095017024130273/ownership.xml","form_type":"4"}},{"id":1354249,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-22T22:00:05.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":1015743,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 1,015,743 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 380,904 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 634,839 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":1015743,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":1015743},"source":{"system":"sec-edgar","filing":"0000950170-24-130272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000095017024130272/ownership.xml","form_type":"4"}},{"id":1354395,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-22T17:00:06.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":474350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 474,350 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 177,881 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 296,469 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":474350,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":474350},"source":{"system":"sec-edgar","filing":"0000950170-24-130278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000095017024130278/ownership.xml","form_type":"4"}},{"id":1379059,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-10-31T21:52:16.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":440489,"price":3.649,"value":1607344.361,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":838507,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":440489},"source":{"system":"sec-edgar","filing":"0000921895-24-002408","document":"form407422eldn_10312024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002408/form407422eldn_10312024.xml","form_type":"4"}},{"id":1379058,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-10-31T21:52:16.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":2100244,"price":3.649,"value":7663790.356,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":6235545,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":2100244},"source":{"system":"sec-edgar","filing":"0000921895-24-002408","document":"form407422eldn_10312024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002408/form407422eldn_10312024.xml","form_type":"4"}},{"id":1379057,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-10-31T21:52:16.000Z","date":"2024-10-29","kind":"purchase","planned":false,"acquired":true,"shares":2213816,"price":3.649,"value":8078214.584,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The pre-funded warrants are exercisable immediately and shall expire when exercised in full. The pre-funded warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":7415596,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":2213816},"source":{"system":"sec-edgar","filing":"0000921895-24-002408","document":"form407422eldn_10312024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524002408/form407422eldn_10312024.xml","form_type":"4"}},{"id":1478954,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T21:00:08.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":517454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 517,454 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 129,363 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 388,091 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":517454,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":517454},"source":{"system":"sec-edgar","filing":"0000950170-24-073772","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000095017024073772/ownership.xml","form_type":"4"}},{"id":1478840,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84183,"kind":"person","name":"Little Paul Sean","position":1,"cik":"0001749385","reported_name":"Little Paul Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T21:00:07.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":267470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 267,470 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 66,867 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 200,603 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":267470,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":267470},"source":{"system":"sec-edgar","filing":"0000950170-24-073771","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024073771/ownership.xml","form_type":"4"}},{"id":1479236,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T21:00:05.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":428148,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 428,148 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 107,037 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 321,111 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":428148,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":428148},"source":{"system":"sec-edgar","filing":"0000950170-24-073770","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000095017024073770/ownership.xml","form_type":"4"}},{"id":1479082,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T17:00:03.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":241650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 241,650 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 60,413 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 181,237 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027."}],"balance_after":241650,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":241650},"source":{"system":"sec-edgar","filing":"0000950170-24-073767","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000095017024073767/ownership.xml","form_type":"4"}},{"id":1519698,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-05-13T21:04:15.000Z","date":"2024-05-09","kind":"purchase","planned":false,"acquired":true,"shares":232068,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\").  Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":232068,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":232068},"source":{"system":"sec-edgar","filing":"0000921895-24-001131","document":"form407422010_05132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001131/form407422010_05132024.xml","form_type":"4"}},{"id":1519697,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-05-13T21:04:15.000Z","date":"2024-05-09","kind":"purchase","planned":false,"acquired":true,"shares":2526238,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\").  Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2526238,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":2526238},"source":{"system":"sec-edgar","filing":"0000921895-24-001131","document":"form407422010_05132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001131/form407422010_05132024.xml","form_type":"4"}},{"id":1519696,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2024-05-13T21:04:15.000Z","date":"2024-05-09","kind":"purchase","planned":false,"acquired":true,"shares":3173135,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\").  Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2024 Pre-Funded Warrants purchased in the 2024 Private Placement. The 2024 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2024 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":3173135,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":3173135},"source":{"system":"sec-edgar","filing":"0000921895-24-001131","document":"form407422010_05132024.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001131/form407422010_05132024.xml","form_type":"4"}},{"id":1519695,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2024-05-13T21:04:15.000Z","date":"2024-05-09","kind":"purchase","planned":false,"acquired":true,"shares":75431,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\").  Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Common Stock purchased in the 2024 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of Common Stock purchased in the 2024 Private Placement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":220460,"source":{"system":"sec-edgar","filing":"0000921895-24-001131","document":"form407422010_05132024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001131/form407422010_05132024.xml","form_type":"4"}},{"id":1519694,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2024-05-13T21:04:15.000Z","date":"2024-05-09","kind":"purchase","planned":false,"acquired":true,"shares":821121,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\").  Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Common Stock purchased in the 2024 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of Common Stock purchased in the 2024 Private Placement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2633679,"source":{"system":"sec-edgar","filing":"0000921895-24-001131","document":"form407422010_05132024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001131/form407422010_05132024.xml","form_type":"4"}},{"id":1519693,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2024-05-13T21:04:15.000Z","date":"2024-05-09","kind":"purchase","planned":false,"acquired":true,"shares":1031385,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\").  Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\") that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock (the \"Common Stock\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Common Stock purchased in the 2024 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to a securities purchase agreement between the Issuer and certain institutional and accredited investors, including certain of the Reporting Persons (the \"2024 Purchasers\"), the Issuer agreed to issue and sell to the 2024 Purchasers in a private placement (the \"2024 Private Placement\") shares of Common Stock at a price of $2.37 per share, and pre-funded warrants (the \"2024 Pre-Funded Warrants\") at a price of $2.369 per underlying share, which are exercisable into shares of Common Stock at an exercise price of $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of Common Stock purchased in the 2024 Private Placement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":3361803,"source":{"system":"sec-edgar","filing":"0000921895-24-001131","document":"form407422010_05132024.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189524001131/form407422010_05132024.xml","form_type":"4"}},{"id":1767079,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":18718,"kind":"person","name":"Robinson James A. Jr.","position":1,"cik":"0001734295","reported_name":"Robinson James A. Jr.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-03T20:19:12.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":150437,"price":1.55,"value":233177.35,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on October 2, 2024 and with respect to 75,218 shares on October 2, 2025."}],"balance_after":150437,"derivative":{"exercise_price":1.55,"expiration_date":"2033-10-02","underlying":"Common Stock","underlying_shares":150437},"source":{"system":"sec-edgar","filing":"0001209191-23-051460","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123051460/doc4.xml","form_type":"4"}},{"id":1767078,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69238,"kind":"person","name":"Kirk Allan","position":1,"cik":"0001995409","reported_name":"Kirk Allan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-03T20:17:59.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":150437,"price":1.55,"value":233177.35,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on October 2, 2024 and with respect to 75,218 shares on October 2, 2025."}],"balance_after":150437,"derivative":{"exercise_price":1.55,"expiration_date":"2033-10-02","underlying":"Common Stock","underlying_shares":150437},"source":{"system":"sec-edgar","filing":"0001209191-23-051456","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123051456/doc4.xml","form_type":"4"}},{"id":1900094,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2023-05-10T00:25:28.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":252291,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"2023 Common Warrants purchased in the 2023 Private Placement. The 2023 Common Warrants are exercisable immediately and have a term of exercise equal to five years. The 2023 Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"2023 Common Warrants purchased in the 2023 Private Placement. The 2023 Common Warrants are exercisable immediately and have a term of exercise equal to five years. The 2023 Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"2023 Common Warrants purchased in the 2023 Private Placement. The 2023 Common Warrants are exercisable immediately and have a term of exercise equal to five years. The 2023 Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":252291,"derivative":{"exercise_price":3,"underlying":"Common Stock, $0.001 par value","underlying_shares":252291},"source":{"system":"sec-edgar","filing":"0000921895-23-001098","document":"form407422eldn_05092023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189523001098/form407422eldn_05092023.xml","form_type":"4"}},{"id":1900093,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2023-05-10T00:25:28.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":2446209,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"2023 Common Warrants purchased in the 2023 Private Placement. The 2023 Common Warrants are exercisable immediately and have a term of exercise equal to five years. The 2023 Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"2023 Common Warrants purchased in the 2023 Private Placement. The 2023 Common Warrants are exercisable immediately and have a term of exercise equal to five years. The 2023 Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"2023 Common Warrants purchased in the 2023 Private Placement. The 2023 Common Warrants are exercisable immediately and have a term of exercise equal to five years. The 2023 Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":2446209,"derivative":{"exercise_price":3,"underlying":"Common Stock, $0.001 par value","underlying_shares":2446209},"source":{"system":"sec-edgar","filing":"0000921895-23-001098","document":"form407422eldn_05092023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189523001098/form407422eldn_05092023.xml","form_type":"4"}},{"id":1900092,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2023-05-10T00:25:28.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":3084090,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"2023 Common Warrants purchased in the 2023 Private Placement. The 2023 Common Warrants are exercisable immediately and have a term of exercise equal to five years. The 2023 Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"2023 Common Warrants purchased in the 2023 Private Placement. The 2023 Common Warrants are exercisable immediately and have a term of exercise equal to five years. The 2023 Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"2023 Common Warrants purchased in the 2023 Private Placement. The 2023 Common Warrants are exercisable immediately and have a term of exercise equal to five years. The 2023 Common Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":3084090,"derivative":{"exercise_price":3,"underlying":"Common Stock, $0.001 par value","underlying_shares":3084090},"source":{"system":"sec-edgar","filing":"0000921895-23-001098","document":"form407422eldn_05092023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189523001098/form407422eldn_05092023.xml","form_type":"4"}},{"id":1900091,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2023-05-10T00:25:28.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":165950,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":165950,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":165950},"source":{"system":"sec-edgar","filing":"0000921895-23-001098","document":"form407422eldn_05092023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189523001098/form407422eldn_05092023.xml","form_type":"4"}},{"id":1900090,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2023-05-10T00:25:28.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":1609063,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":1609063,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":1609063},"source":{"system":"sec-edgar","filing":"0000921895-23-001098","document":"form407422eldn_05092023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189523001098/form407422eldn_05092023.xml","form_type":"4"}},{"id":1900089,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants to Purchase Common Stock","published_at":"2023-05-10T00:25:28.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":2028645,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"2023 Pre-Funded Warrants purchased in the 2023 Private Placement. The 2023 Pre-Funded Warrants are exercisable immediately and shall expire when exercised in full. The 2023 Pre-Funded Warrants cannot be exercised by the Reporting Persons if, after giving effect thereto, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the outstanding shares of Common Stock, subject to certain exceptions."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":2028645,"derivative":{"exercise_price":0.001,"underlying":"Common Stock, $0.001 par value","underlying_shares":2028645},"source":{"system":"sec-edgar","filing":"0000921895-23-001098","document":"form407422eldn_05092023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189523001098/form407422eldn_05092023.xml","form_type":"4"}},{"id":1900088,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2023-05-10T00:25:28.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":86341,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Common Stock purchased in the 2023 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of Common Stock purchased in the 2023 Private Placement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":145029,"source":{"system":"sec-edgar","filing":"0000921895-23-001098","document":"form407422eldn_05092023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189523001098/form407422eldn_05092023.xml","form_type":"4"}},{"id":1900087,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2023-05-10T00:25:28.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":837146,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Common Stock purchased in the 2023 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of Common Stock purchased in the 2023 Private Placement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":1812558,"source":{"system":"sec-edgar","filing":"0000921895-23-001098","document":"form407422eldn_05092023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189523001098/form407422eldn_05092023.xml","form_type":"4"}},{"id":1900086,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2023-05-10T00:25:28.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":1055445,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Common Stock purchased in the 2023 Private Placement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Issuer entered into a Securities Purchase Agreement with certain institutional and accredited investors, including certain of the Reporting Persons (the \"Purchasers\"), pursuant to which the Issuer agreed to issue and sell to the Purchasers in a private placement (the \"2023 Private Placement\"), in an initial closing, shares of the Issuer's Common Stock or pre-funded warrants in lieu thereof (the \"2023 Pre-Funded Warrants\"), and common stock warrants exercisable into shares of Common Stock (or 2023 Pre-Funded Warrants in lieu thereof) (the \"2023 Common Warrants\") at a per share purchase price equal to $2.31 (less $0.001 for each Pre-Funded Warrant, as applicable)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of Common Stock purchased in the 2023 Private Placement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":2330418,"source":{"system":"sec-edgar","filing":"0000921895-23-001098","document":"form407422eldn_05092023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189523001098/form407422eldn_05092023.xml","form_type":"4"}},{"id":1908479,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T22:50:07.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":317147,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 317,147 shares of Common Stock, which option vests with respect to 79,287 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027."}],"balance_after":317147,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":317147},"source":{"system":"sec-edgar","filing":"0001209191-23-026733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000120919123026733/doc4.xml","form_type":"4"}},{"id":1908292,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock (right to buy)","published_at":"2023-05-02T22:49:08.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":383299,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 383,299 shares of Common Stock, which option vests with respect to 95,825 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027."}],"balance_after":383299,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":383299},"source":{"system":"sec-edgar","filing":"0001209191-23-026732","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919123026732/doc4.xml","form_type":"4"}},{"id":1908126,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":114004,"kind":"person","name":"Ogier Walter C","position":1,"cik":"0001344644","reported_name":"Ogier Walter C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T22:48:35.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":150437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025."}],"balance_after":150437,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":150437},"source":{"system":"sec-edgar","filing":"0001209191-23-026731","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123026731/doc4.xml","form_type":"4"}},{"id":1908125,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84183,"kind":"person","name":"Little Paul Sean","position":1,"cik":"0001749385","reported_name":"Little Paul Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T22:47:47.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":198126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 198,126 shares of Common Stock, which option vests with respect to 49,531 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027."}],"balance_after":198126,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":198126},"source":{"system":"sec-edgar","filing":"0001209191-23-026730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123026730/doc4.xml","form_type":"4"}},{"id":1908124,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T22:45:57.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":752185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 752,185 shares of Common Stock, which option vests with respect to 376,093 shares on May 1, 2024 and with respect to 376,092 shares on May 1, 2025."}],"balance_after":752185,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":752185},"source":{"system":"sec-edgar","filing":"0001209191-23-026728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123026728/doc4.xml","form_type":"4"}},{"id":1908832,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-02T22:44:12.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":150437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025."}],"balance_after":150437,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":150437},"source":{"system":"sec-edgar","filing":"0001209191-23-026725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919123026725/doc4.xml","form_type":"4"}},{"id":1908123,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":43099,"kind":"person","name":"Lee June","position":1,"cik":"0001696493","reported_name":"Lee June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T22:43:30.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":150437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025."}],"balance_after":150437,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":150437},"source":{"system":"sec-edgar","filing":"0001209191-23-026724","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123026724/doc4.xml","form_type":"4"}},{"id":1908392,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T18:50:38.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":179000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 179,000 shares of Common Stock, which option vests with respect to 44,750 shares on May 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending May 1, 2027."}],"balance_after":179000,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":179000},"source":{"system":"sec-edgar","filing":"0001209191-23-026734","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000120919123026734/doc4.xml","form_type":"4"}},{"id":1908283,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69246,"kind":"person","name":"McBride John S.","position":1,"cik":"0001618251","reported_name":"McBride John S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T18:44:49.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":150437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025."}],"balance_after":150437,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":150437},"source":{"system":"sec-edgar","filing":"0001209191-23-026727","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618251/000120919123026727/doc4.xml","form_type":"4"}},{"id":1908513,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69252,"kind":"person","name":"Hillson Jan","position":1,"cik":"0001871936","reported_name":"Hillson Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-02T18:42:47.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":150437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025."}],"balance_after":150437,"derivative":{"exercise_price":2.3,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":150437},"source":{"system":"sec-edgar","filing":"0001209191-23-026721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871936/000120919123026721/doc4.xml","form_type":"4"}},{"id":2036464,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T23:11:58.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2027."}],"balance_after":155000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-23-006364","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000120919123006364/doc4.xml","form_type":"4"}},{"id":2035746,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":114004,"kind":"person","name":"Ogier Walter C","position":1,"cik":"0001344644","reported_name":"Ogier Walter C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T23:10:03.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024."}],"balance_after":20000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-006359","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123006359/doc4.xml","form_type":"4"}},{"id":2036695,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T23:07:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024."}],"balance_after":20000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-006351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919123006351/doc4.xml","form_type":"4"}},{"id":2035745,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":43099,"kind":"person","name":"Lee June","position":1,"cik":"0001696493","reported_name":"Lee June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T23:05:38.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024."}],"balance_after":20000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-006345","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123006345/doc4.xml","form_type":"4"}},{"id":2035744,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T23:04:04.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024."}],"balance_after":20000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-006339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123006339/doc4.xml","form_type":"4"}},{"id":2036094,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:56:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":153600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on February 1, 2022. The option satisfied the performance criteria with respect to 153,600 shares of underlying Common Stock and these credited shares will satisfy the time-based vesting criteria with respect to 38,400 shares of Common Stock on February 1, 2023, and then with respect to 1/48th of the credited shares monthly over the three-year period ending February 1, 2026."}],"balance_after":153600,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":153600},"source":{"system":"sec-edgar","filing":"0001209191-23-006324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919123006324/doc4.xml","form_type":"4"}},{"id":2036093,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:56:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 300,000 shares of Common Stock, which options vests with respect to 75,000 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three year period ending February 1, 2027."}],"balance_after":300000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-23-006324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919123006324/doc4.xml","form_type":"4"}},{"id":2035743,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84183,"kind":"person","name":"Little Paul Sean","position":1,"cik":"0001749385","reported_name":"Little Paul Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T22:40:44.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2027."}],"balance_after":155000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-23-006300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919123006300/doc4.xml","form_type":"4"}},{"id":2036068,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69246,"kind":"person","name":"McBride John S.","position":1,"cik":"0001618251","reported_name":"McBride John S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T18:08:39.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024."}],"balance_after":20000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-006355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618251/000120919123006355/doc4.xml","form_type":"4"}},{"id":2036521,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69252,"kind":"person","name":"Hillson Jan","position":1,"cik":"0001871936","reported_name":"Hillson Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T17:58:10.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024."}],"balance_after":20000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-006329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871936/000120919123006329/doc4.xml","form_type":"4"}},{"id":2036283,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T17:43:57.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2024, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2027."}],"balance_after":155000,"derivative":{"exercise_price":3.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-23-006309","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000120919123006309/doc4.xml","form_type":"4"}},{"id":2105386,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-11-23T21:05:35.000Z","date":"2022-11-23","kind":"purchase","acquired":true,"shares":1000,"price":2.5969,"value":2596.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports an open market purchase by the Reporting Person of shares of common stock in accordance with the Issuer's trading policies."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001209191-22-058608","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000120919122058608/doc4.xml","form_type":"4"}},{"id":2416652,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:38:38.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":108000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 108,000 shares of Common Stock, which option vests with respect to 27,000 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026."}],"balance_after":108000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001209191-22-006492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919122006492/doc4.xml","form_type":"4"}},{"id":2416992,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26682,"kind":"person","name":"Perrin Steven","position":1,"cik":"0001824545","reported_name":"Perrin Steven","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:37:02.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026."}],"balance_after":155000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-22-006486","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824545/000120919122006486/doc4.xml","form_type":"4"}},{"id":2416282,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":114004,"kind":"person","name":"Ogier Walter C","position":1,"cik":"0001344644","reported_name":"Ogier Walter C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:36:28.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023."}],"balance_after":20000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-006485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919122006485/doc4.xml","form_type":"4"}},{"id":2417156,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":21784,"kind":"person","name":"LYONS GARY A","position":1,"cik":"0001123343","reported_name":"LYONS GARY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:33:31.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023."}],"balance_after":20000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-006476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123343/000120919122006476/doc4.xml","form_type":"4"}},{"id":2416281,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":43099,"kind":"person","name":"Lee June","position":1,"cik":"0001696493","reported_name":"Lee June","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:32:07.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023."}],"balance_after":20000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-006471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919122006471/doc4.xml","form_type":"4"}},{"id":2416280,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":49925,"kind":"person","name":"Katkin Keith","position":1,"cik":"0001314596","reported_name":"Katkin Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:30:16.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023."}],"balance_after":20000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-006466","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919122006466/doc4.xml","form_type":"4"}},{"id":2416279,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84183,"kind":"person","name":"Little Paul Sean","position":1,"cik":"0001749385","reported_name":"Little Paul Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T22:23:24.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 155,000 shares of Common Stock, which option vests with respect to 38,750 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026."}],"balance_after":155000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001209191-22-006446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000120919122006446/doc4.xml","form_type":"4"}},{"id":2416848,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84192,"kind":"person","name":"Smith Bryan E.","position":1,"cik":"0001748041","reported_name":"Smith Bryan E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Corporate Sec"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T17:37:52.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 120,000 shares of Common Stock, which option vests with respect to 30,000 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026."}],"balance_after":120000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-22-006489","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748041/000120919122006489/doc4.xml","form_type":"4"}},{"id":2416635,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69246,"kind":"person","name":"McBride John S.","position":1,"cik":"0001618251","reported_name":"McBride John S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T17:35:01.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023."}],"balance_after":20000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-006480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1618251/000120919122006480/doc4.xml","form_type":"4"}},{"id":2417117,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":69252,"kind":"person","name":"Hillson Jan","position":1,"cik":"0001871936","reported_name":"Hillson Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T17:29:37.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023."}],"balance_after":20000,"derivative":{"exercise_price":3.97,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-006464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871936/000120919122006464/doc4.xml","form_type":"4"}},{"id":2462445,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-21T21:05:34.000Z","date":"2021-12-20","kind":"purchase","acquired":true,"shares":2000,"price":4.48,"value":8960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were purchased in an open market transaction in accordance with the Issuer's trading policies."}],"balance_after":9000,"source":{"system":"sec-edgar","filing":"0000899243-21-049171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000089924321049171/doc4.xml","form_type":"4"}},{"id":2596193,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-19T20:05:24.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":4000,"price":6.21,"value":24840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple open market transactions in accordance with the Issuer's trading policies at prices ranging from $6.20 to $6.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001209191-21-052519","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000120919121052519/doc4.xml","form_type":"4"}},{"id":2669977,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":84183,"kind":"person","name":"Little Paul Sean","position":1,"cik":"0001749385","reported_name":"Little Paul Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2021-06-14T21:24:30.000Z","date":"2021-06-11","kind":"purchase","acquired":true,"shares":10000,"price":8.87,"value":88700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple open market transactions in accordance with the Issuer's trading policies at prices ranging from $8.76 to $8.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-21-023640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000089924321023640/doc4.xml","form_type":"4"}},{"id":2673969,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":26643,"kind":"person","name":"Gros David-Alexandre C","position":1,"cik":"0001644489","reported_name":"Gros David-Alexandre C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-10T21:25:51.000Z","date":"2021-06-09","kind":"purchase","acquired":true,"shares":3000,"price":8.01,"value":24030.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports an open market purchase by the Reporting Person of shares of common stock in accordance with the Issuer's trading policies."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-21-022998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644489/000089924321022998/doc4.xml","form_type":"4"}}],"next_cursor":"2021-06-10T21:25:51.000000Z,2673969"}